Abstract
Radiomic features are quantitative data calculated from routine medical images and have shown great potential for disease phenotyping and risk stratification in cancer. Patients with systemic sclerosis (SSc), a multi-organ autoimmune disorder, have a similarly poor prognosis (10-year survival of 66%), due to interstitial lung disease (ILD) as the primary cause of death. Here, we present the analysis of 1,355 stable radiomic features extracted from computed tomography scans from 156 SSc-ILD patients, which describe distinct disease phenotypes and show prognostic power in two independent cohorts. We derive and externally validate a first quantitative radiomic risk score, qRISSc that accurately predicts progression-free survival in SSc-ILD and outperforms current clinical stratification measures. Correlation analysis with lung proteomics, histology and gene expression data in a cross-species approach demonstrates that qRISSc reverse translates into mice and captures the fibrotic remodeling process in experimental ILD.
Competing Interest Statement
J.S., M.M., H.S.G, M.B., C.M., C.B., M.G., S.B., A.U., M.H., C.T.N., T.F, S.T. have no competing interests to declare. O.D. had consultancy relationship and/or has received research funding from Abbvie, Actelion, Acceleron Pharma, Amgen, AnaMar, Baecon Discovery, Blade Therapeutics, Bayer, Boehringer Ingelheim, Catenion, Competitive Drug Development International Ltd, CSL Behring, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, Glenmark Pharmaceuticals, GSK, Inventiva, Italfarmaco, iQone, iQvia, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Target Bio Science and UCB in the area of potential treatments of scleroderma and its complications. In addition, O.D. has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143). H.F. received travel bursaries from Actelion and GSK, and remuneration from Bayer. A.M.H.V had grant/research support from Boehringer-Ingelheim and received speaker and personal fees from Boehringer-Ingelheim, Roche, Actelion, and Bayer. B. M. had grant/research support from AbbVie, Protagen, Novartis Biomedical Research as well as congress support from Pfizer, Roche, Actelion, and MSD. In addition, B.M. has a patent mir-29 for the treatment of systemic sclerosis registered (US8247389, EP2331143). This work was supported by the Forschungskredit PostDoc from University of Zurich (to J.S.; FK-19-046), the Bangerter Foundation and Swiss Academy of Medical Sciences (to C.M.), as well as the Gebauer Foundation, Lunge Zurich Foundation, OPO Foundation, and Prof. Max Cloetta Foundation (to B.M.).
Funding Statement
This work was supported by the Forschungskredit PostDoc from University of Zurich (to J.S.; FK-19-046), the Bangerter Foundation and Swiss Academy of Medical Sciences (to C.M.), as well as the Gebauer Foundation, Lunge Zurich Foundation, OPO Foundation, and Prof. Max Cloetta Foundation (to B.M.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local ethics committees (approval numbers: pre-BASEC-EK-839 (KEK-no.-2016-01515), KEK-ZH-no. 2010-158/5, BASEC-no. 2018-02165) and written informed consent was obtained from every patient.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
For data and material requests please contact the corresponding author (britta.maurer{at}usz.ch).
